StockWatch
·

Concord Drugs Ltd Q3 FY25 Results

CONCORDQ3 FY25 Results
Filing
MetricValue ( Cr)vs Q2 FY25
Revenue10.8012.6%
Total Income10.8012.7%
Expenditure10.2716.5%
PBT0.53698.5%
Net Profit0.23415.9%
OPM-3.15%2.95pp
NPM2.10%1.74pp
EPS0.23475.0%
View full financials

Informational and educational content only. Not investment advice.